Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies

Introduction: NSCLC with MET exon 14 skipping mutation (METex14) is associated with poor outcomes. Integration of novel targeted therapies is challenging because of barriers in testing and drug access. We, therefore, sought to characterize the treatment patterns, outcomes, and emerging issues of tre...

Full description

Bibliographic Details
Main Authors: Sally C.M. Lau, MD, MPH, Kirstin Perdrizet, MD, Andrea S. Fung, MD, PhD, Danilo Giffoni M.M. Mata, MD, Jessica Weiss, PhD, Nick Holzapfel, MD, Geoffrey Liu, MD, Penelope A. Bradbury, MD, Frances A. Shepherd, MD, Adrian G. Sacher, MD, MMSc, Harriet Feilotter, MD, Brandon Sheffield, MD, David Hwang, MD, Ming Sound Tsao, MD, Susanna Cheng, MD, Parneet Cheema, MD, Natasha B. Leighl, MD, MMSc
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
MET inhibitors
MET exon 14 skipping
PD1 inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001054

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001054

Similar Items